Literature DB >> 12117461

Renal protection by antihypertensive therapy.

Luis M Ruilope1, Julian Segura.   

Abstract

The attainment of adequate renal protection requires strict blood pressure control and a diminution of proteinuria or microalbuminuria to values as near from normalcy as possible. It has been considered that by getting the first, the second could be attained at the same price. Recent data have confirmed that renal protection in hypertensive patients, diabetics or not, requires combination therapy that has to include an angiotensin converting enzyme inhibitor or an angiotensin receptor blocker. A calcium channel blocker can be added to this without renal compromise. A diuretic will also be needed in most cases. Proteinuria will diminish with this combination in particular if up-titration of the drug blocking the effects of angiotensin II is performed. The control of other associated risk factors is also required, in particular smoking and lipids.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12117461     DOI: 10.1007/s11906-996-0012-0

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  43 in total

1.  Hypertensive vascular disease; description and natural history.

Authors:  G A PERERA
Journal:  J Chronic Dis       Date:  1955-01

2.  Therapeutic efficacy of different antihypertensive drugs in human diabetic nephropathy: an updated meta-analysis.

Authors:  P Weidmann; M Schneider; L Böhlen
Journal:  Nephrol Dial Transplant       Date:  1995-10       Impact factor: 5.992

Review 3.  Blood pressure control, proteinuria and renal outcome in chronic renal failure.

Authors:  L M Ruilope; C Campo; J L Rodicio
Journal:  Curr Opin Nephrol Hypertens       Date:  1998-03       Impact factor: 2.894

4.  Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.

Authors:  J F Mann; H C Gerstein; J Pogue; J Bosch; S Yusuf
Journal:  Ann Intern Med       Date:  2001-04-17       Impact factor: 25.391

5.  Dissociation between blood pressure reduction and fall in proteinuria in primary renal disease: a randomized double-blind trial.

Authors: 
Journal:  J Hypertens       Date:  2002-04       Impact factor: 4.844

Review 6.  Pathophysiology of obesity hypertension.

Authors:  J E Hall
Journal:  Curr Hypertens Rep       Date:  2000-04       Impact factor: 5.369

7.  Kidneys and primary hypertension--initiators, stabilizers or/and victim-aggravators?

Authors:  B Folkow
Journal:  Blood Press       Date:  1994-07       Impact factor: 2.835

8.  Renal function during antihypertensive treatment.

Authors:  S Madhavan; D Stockwell; H Cohen; M H Alderman
Journal:  Lancet       Date:  1995-03-25       Impact factor: 79.321

9.  Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group.

Authors:  N B Shulman; C E Ford; W D Hall; M D Blaufox; D Simon; H G Langford; K A Schneider
Journal:  Hypertension       Date:  1989-05       Impact factor: 10.190

Review 10.  Renal consequences of arterial hypertension.

Authors:  L M Ruilope; J M Alcázar; J L Rodicio
Journal:  J Hypertens Suppl       Date:  1992-12
View more
  2 in total

1.  African American hypertensive nephropathy maps to a new locus on chromosome 9q31-q32.

Authors:  Ki Wha Chung; Robert E Ferrell; Demetrius Ellis; Michael Barmada; Michael Moritz; David N Finegold; Ronald Jaffe; Abhay Vats
Journal:  Am J Hum Genet       Date:  2003-07-01       Impact factor: 11.025

2.  Efficacy and Safety of Olmesartan in the Treatment of Mild-to-Moderate Essential Hypertension in Chinese Patients.

Authors:  Chiau-Suong Liau; Chii-Ming Lee; Sheng-Hsiung Sheu; Kwo-Chang Ueng; Kuo-Liong Chien; Ta-Chen Su; Wen-Ter Lai; Ming-Cheng Lin; Cheng-Sheng Lin; Chung-Sheng Lin
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.